MNOV Key Statistics, Chart & Performance
The current stock price of MNOV is 1.5 USD. In the past month the price decreased by -3.82%. In the past year, price decreased by -28.1%.
MNOV Latest News, Press Relases and Analysis
MNOV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.49 | 392.34B | ||
| AMGN | AMGEN INC | 14.42 | 169.76B | ||
| GILD | GILEAD SCIENCES INC | 14.92 | 151.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26 | 114.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.38 | 77.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.24 | 51.69B | ||
| INSM | INSMED INC | N/A | 41.46B | ||
| NTRA | NATERA INC | N/A | 31.69B | ||
| BIIB | BIOGEN INC | 10.34 | 25.40B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.61 | 21.14B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.61 | 18.41B |
Related stock screener links
About MNOV
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Company Info
MEDICINOVA INC
4275 Executive Square, Suite 300
La Jolla CALIFORNIA 92037 US
CEO: Yuichi Iwaki
Employees: 13
Phone: 18583731500
MEDICINOVA INC / MNOV FAQ
What does MEDICINOVA INC do?
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
What is the current price of MNOV stock?
The current stock price of MNOV is 1.5 USD. The price decreased by -0.66% in the last trading session.
What is the dividend status of MEDICINOVA INC?
MNOV does not pay a dividend.
What is the ChartMill rating of MEDICINOVA INC stock?
MNOV has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of MEDICINOVA INC (MNOV) based on its PE ratio?
MEDICINOVA INC (MNOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
Who owns MEDICINOVA INC?
You can find the ownership structure of MEDICINOVA INC (MNOV) on the Ownership tab.
What is the Short Interest ratio of MEDICINOVA INC (MNOV) stock?
The outstanding short interest for MEDICINOVA INC (MNOV) is 1.19% of its float.
MNOV Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MNOV. When comparing the yearly performance of all stocks, MNOV is a bad performer in the overall market: 66.73% of all stocks are doing better.
MNOV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNOV. MNOV has a great financial health rating, but its profitability evaluates not so good.
MNOV Financial Highlights
Over the last trailing twelve months MNOV reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -19.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.22% | ||
| ROE | -25.13% | ||
| Debt/Equity | 0 |
MNOV Forecast & Estimates
8 analysts have analysed MNOV and the average price target is 7.14 USD. This implies a price increase of 376% is expected in the next year compared to the current price of 1.5.